<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7493775\results\search\drug\results.xml">
  <result pre="repurposing of broadly acting antiviral drugs such as IFNs and" exact="ribavirin" post="that have been used for other viral infections or"/>
  <result pre="for the development of novel anti-SARS-CoV-2 therapy. 2.2. RdRp inhibition" exact="Ribavirin" post="is a broad-spectrum antiviral agent that has previously been"/>
  <result pre="RNA and capping of mRNA. During the previous SARS epidemic," exact="ribavirin" post="was widely used for patients in China.15 However, evidence"/>
  <result pre="was widely used for patients in China.15 However, evidence showed" exact="ribavirin" post="might have no significant antiviral activity against SARS-CoV in"/>
  <result pre="vitro and had significant toxicity concern in clinical practice.16,17 Hence," exact="ribavirin" post="usage for SARS-CoV is questionable and has been criticized.18"/>
  <result pre="has been criticized.18 Earlier evidence demonstrated that the combination of" exact="ribavirin" post="and IFN-Î² had a synergistic effect for inhibiting the"/>
  <result pre="of the in vitro efficacy for SARS-CoV, the usage of" exact="ribavirin" post="against SARS-CoV-2 should be carefully considered. Remdesivir, by far,"/>
  <result pre="COVID-19 is ongoing (ChiCTR2000029600). 2.3. Protease inhibition A co-formulation of" exact="lopinavir" post="and ritonavir, which was reported to have in vitro"/>
  <result pre="been tested for the therapy of COVID-19.23â€&quot;25 The component of" exact="lopinavir" post="can bind to HIV-1 protease and block the cleavage"/>
  <result pre="particles. Another component, ritonavir, can increase the plasma level of" exact="lopinavir" post="by inhibiting the CYP3A-mediated metabolism of the latter. It"/>
  <result pre="been shown to inhibit the replication of SARS-CoV.30 In addition," exact="nelfinavir" post="has revealed rational binding conformation with the viral main"/>
  <result pre="with the viral main protease of SARS-CoV-2. (BioRxiv doi:10.1101/2020.01.28.922922.) Therefore," exact="nelfinavir" post="might be a potential therapeutic option for COVID-19. 2.4."/>
  <result pre="developing new drugs to fight COVID-19. 2.5. Viral entry inhibitors" exact="Hydroxychloroquine" post="and chloroquine are aminoquinolines, which have been used to"/>
  <result pre="drugs to fight COVID-19. 2.5. Viral entry inhibitors Hydroxychloroquine and" exact="chloroquine" post="are aminoquinolines, which have been used to treat autoimmune"/>
  <result pre="of the endosomes, which in turn prevent viral entry fusion.35" exact="Chloroquine" post="can also interfere with ACE2 glycosylation of the cellular"/>
  <result pre="ChiCTR2000029609). The preliminary study in France evaluated the efficacy of" exact="hydroxychloroquine" post="in SARS-CoV-2 patients. The results showed that the virologic"/>
  <result pre="is still under investigation. Hence, the benefits and risk of" exact="chloroquine" post="or hydroxychloroquine therapy for COVID-19 remains to be carefully"/>
  <result pre="under investigation. Hence, the benefits and risk of chloroquine or" exact="hydroxychloroquine" post="therapy for COVID-19 remains to be carefully elucidated. 2.6."/>
  <result pre="entry also depends on transmembrane protease serine 2 (TMPRSS2).37 Hence," exact="camostat" post="mesylate, a TMPRSS2 inhibitor, can eliminate SARS-CoV-2 infection in"/>
  <result pre="process. It provides potential target for COVID-19 therapy development. Recently," exact="amantadine" post="was screened for the possibility to downregulate the expression"/>
  <result pre="evidence indicated its poor activity against SARS-CoV.16 At present, the" exact="amantadine" post="and its analog are not recommended for influenza due"/>
  <result pre="effect on lactation due to decrease of serum prolactin.46 Although" exact="amantadine" post="and its analog are not commonly discussed, this aspect"/>
  <result pre="equine encephalitis virus in vitro.69â€&quot;72 Initially, the inhibitory activity of" exact="ivermectin" post="on interaction of virus integrase protein (IN) and the"/>
  <result pre="IMPÎ±/Î²1 on the rough ER/Golgi membrane.81 The evidence suggests that" exact="ivermectin" post="might be used against SARS-CoV-2 through nuclear transport inhibitory"/>
  <result pre="an in vitro experiment showed that a single treatment with" exact="ivermectin" post="resulted in about 5000-fold reduction in SARS-CoV-2 virus.82 The"/>
  <result pre="on its in vitro efficacy and a well-known safety information," exact="ivermectin" post="might be worthy to further evaluate as a potential"/>
  <result pre="with severe Covid-19.N Engl J Med2020;382:1787â€&quot;99.32187464 30.YamamotoNYangRYoshinakaYAmariSNakanoTCinatlJet al.HIV protease inhibitor" exact="nelfinavir" post="inhibits replication of SARS-associated coronavirus.Biochem Biophys Res Commun2004;318:719â€&quot;25.15144898 31.ParkJYJeongHJKimJHKimYMParkSJKimDet"/>
  <result pre="inhibits autophagic flux by decreasing autophagosome-lysosome fusion.Autophagy2018;14:1435â€&quot;55.29940786 36.GautretPLagierJCParolaPHoangVTMeddebLMailheMet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  <result pre="Res2020;30:189â€&quot;90.32071427 66.Ben AddiALefortAHuaXLibertFCommuniDLedentCet al.Modulation of murine dendritic cell function by" exact="adenine" post="nucleotides and adenosine: involvement of the A(2B) receptor.Eur J"/>
  <result pre="on the rough endoplasmic reticulum/Golgi membrane.J Virol2007;81:9812â€&quot;24.17596301 82.CalyLDruceJDCattonMGJansDAWagstaffKMThe FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitro.Antiviral Res2020;178:104787.32251768"/>
 </snippets>
</snippetsTree>
